文献速递血栓与止血

艾美赛珠单抗用于婴儿A型血友病(HA)预防治疗(HAVEN 7):3b期开放标签试验的主要分析

Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.
PubMed 文献 · Blood · 2024-01-01

HAVEN 7是一项3b期开放标签试验,纳入55例≤12个月且无FVIII抑制物的重型A型血友病男婴,接受艾美赛珠单抗3 mg/kg每2周维持治疗52周。模型基础年化出血率(治疗性出血)为0.4(95%CI 0.30-0.63),54.5%的受试者无治疗性出血,无颅内出血发生。9例(16.4%)发生≥1次艾美赛珠单抗相关不良事件(均为1级注射部位反应),无死亡、血栓栓塞事件或血栓性微血管病,2例确认FVIII抑制物阳性。

要点

  • 艾美赛珠单抗3 mg/kg每2周预防治疗婴儿重型A型血友病,模型基础治疗性出血年化出血率为0.4(95%CI 0.30-0.63)。
  • 54.5%的受试者(n=30)无治疗性出血,未发生颅内出血。
  • 9例(16.4%)发生艾美赛珠单抗相关不良事件,均为1级注射部位反应;无死亡、血栓栓塞事件或血栓性微血管病。

核心结论

  • HAVEN 7主要分析表明,艾美赛珠单抗在无FVIII抑制物的重型A型血友病婴儿中有效且耐受性良好。

研究设计与样本

  • HAVEN 7(NCT04431726)是首个专门针对婴儿的艾美赛珠单抗临床试验,为3b期开放标签试验。
  • 纳入年龄≤12个月、重型A型血友病且无FVIII抑制物的婴儿,接受艾美赛珠单抗3 mg/kg维持剂量每2周一次,治疗52周,并在7年长期随访中继续使用。
  • 主要分析时,55例男性受试者已接受艾美赛珠单抗治疗,中位治疗持续时间100.3周(范围52-118周)。
  • 知情同意时中位年龄4.0个月(范围9天至11个月30天)。

主要发现

  • 模型基础治疗性出血年化出血率为0.4(95%置信区间0.30-0.63),54.5%的受试者(n=30)无治疗性出血。
  • 未发生颅内出血。
  • 25例受试者(45.5%)共发生42次治疗性出血,均为创伤性。
  • 9例受试者(16.4%)发生≥1次艾美赛珠单抗相关不良事件,均为1级注射部位反应;无不良事件导致治疗改变。
  • 无死亡、血栓栓塞事件或血栓性微血管病发生;无受试者抗药抗体检测阳性;2例受试者确认FVIII抑制物阳性。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Subcutaneous emicizumab enables prophylaxis for people with hemophilia A (HA) from birth, potentially reducing risk of bleeding and intracranial hemorrhage (ICH). HAVEN 7 (NCT04431726) is the first clinical trial of emicizumab dedicated to infants, designed to investigate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab in those aged ≤12 months with severe HA without factor VIII (FVIII) inhibitors. Participants in this phase 3b trial received emicizumab 3 mg/kg maintenance dose every 2 weeks for 52 weeks and are continuing emicizumab during the 7-year long-term follow-up. Efficacy end points included annualized bleed rate (ABR): treated, all, treated spontaneous, and treated joint bleeds. Safety end points included adverse events (AEs), thromboembolic events (TEs), thrombotic microangiopathies (TMAs), and immunogenicity (anti-emicizumab antibodies [ADAs] and FVIII inhibitors). At primary analysis, 55 male participants had received emicizumab (median treatment duration: 100.3; range, 52-118 weeks). Median age at informed consent was 4.0 months (range, 9 days to 11 months 30 days). Model-based ABR for treated bleeds was 0.4 (95% confidence interval, 0.30-0.63), with 54.5% of participants (n = 30) having zero treated bleeds. No ICH occurred. All 42 treated bleeds in 25 participants (45.5%) were traumatic. Nine participants (16.4%) had ≥1 emicizumab-related AE (all grade 1 injection-site reactions). No AE led to treatment changes. No deaths, TEs, or TMAs occurred. No participant tested positive for ADAs. Two participants were confirmed positive for FVIII inhibitors. This primary analysis of HAVEN 7 indicates that emicizumab is efficacious and well tolerated in infants with severe HA without FVIII inhibitors.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pipe SW, Collins P, Dhalluin C, et al. Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. Blood. 2024. PMID: 38127586. doi:10.1182/blood.2023021832

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。